|
|
|
| Inhibition of Osteoporosis in Ovariectomized Rats Using Follicle-stimulating Hormone Receptor Specific Polyclonal Antibody |
| QIN Rui-ping, LI Ling-xia, MA Xiao-ling, XI Ou-yan, ZHAO Ting, QIU Ling-ling, LI Jiang-wei |
| Xinjiang Key Laboratory of Biological Resources and Genetic Engineering, College of Life Science and Technology, Xinjiang University, Urumqi 830046, China |
|
|
|
Abstract There are strong evidences to support the idea that follicle-stimulating hormone (FSH) plays an important role in regulation of bone mass. Owing to its limited expression to gonadal tissues and osteoclasts and its precursor monocytes, FSH receptor may be a good target for FSH blocking therapy. High titers of polyclonal rabbit anti-human FSHR antibody (pAbFSHR) was raised and prepared. The bilateral ovariectomized (OVX) Sprague-Dawley (SD) rats were used as the osteoporosis model for evaluating the effects of pAbFSHR and FSH inhibitor leuprorelin(LE) on the bone loss. The results showed after treatment with pAbFSHR and LE separately, the FSH and luteinizing hormone(LH) levels in OVX groups decreased significantly (P<0.05) compared with PBS treated OVX rats. No significant differences of estrogen (E2) levels were detected between treatment and PBS injected OVX rats (P>0.05). In addition, the number of trabecular bone increased after pAbFSHR treatment in OVX groups in the shin bone histologic analysis. The results suggested targeting against FSHR may work on the treatment of osteoporosis.
|
|
Received: 27 December 2016
Published: 25 June 2017
|
|
|
|
|
[1] Kim J H, Kim E Y, Lee B, et al. The effects of Lycii Radicis Cortex on RANKL-induced osteoclast differentiation and activation in RAW 264.7 cells. International Journal of Molecular Medicine, 2016,37(3):649-658.
[2] 潘德, 郝秋芳, 王玮,等. 绝经老年妇女骨质疏松调查及影响因素分析. 中国老年学杂志, 1994,14(6):352-354. Pan D, Hao Q F, Wang W,et al. Older women menopause osteoporosis research and influence factors analysis. Chinese Journal of Gerontology,1994,14(6):352-354.
[3] Zhu L L, Blair H, Cao J,et al. Blocking antibody to the β-subunit of FSH prevents bone loss by inhibiting bone resorption and stimulating bone synthesis. Proceedings of the National Academy of Sciences, 2012, 109(36):14574-14579.
[4] Cannon J G, Cortez-Cooper M, Meaders E, et al. Follicle-stimulating hormone, interleukin-1, and bone density in adult women. American Journal of Physiology-Regulatory,Integrative and Comparative Physiology, 2010, 298(3):R790-R798.
[5] Wang J, Zhang W, Yu C, et al. Follicle-stimulating hormone increases the risk of postmenopausal osteoporosis by stimulating osteoclast differentiation. PloS One, 2015, 10(8):e0134986.
[6] Liu S, Cheng Y, Xu W, et al. Protective effects of follicle-stimulating hormone inhibitor on alveolar bone loss resulting from experimental periapical lesions in ovariectomized rats. Journal of endodontics, 2010, 36(4):658-663.
[7] Sun L, Peng Y, Sharrow A C, et al. FSH directly regulates bone mass. Cell, 2006, 125(2):247-260.
[8] Sun L, Zhang Z, Zhu L L, et al. Further evidence for direct pro-resorptive actions of FSH.Biochemical and Biophysical Research Communications, 2010, 394(1):6-11.
[9] 夏雪琴, 木亚沙尔·买买提拉洪, 翟田甜,等. 抗卵泡刺激素受体纳米抗体的制备及鉴定. 细胞与分子免疫学杂志, 2013, 29(8):829-833. Xia X Q, Mu Y S, Zhai T T,et al. Preparation and identification of anti-follicle-stimulating hormone receptor nanobodies. Chin J Cell Mol Immunol,2013,29(8):829-833.
[10] 卢勇, 孟庆才, 方锐,等. SD大鼠骨性关节炎合并骨质疏松症模型的建立. 中国组织工程研究与临床康复, 2009, 13(46):9092-9096. Lu Y, Meng Q C, Fang R,et al. Establishment of SD rat models of osteoarthritis and osteoporosis. Journal of Clinical Rehabilitative Tissue Engineering Research,2009,13(46):9092-9096.
[11] 田茂友, 李洪洋.去卵巢大鼠骨质疏松模型研究. 现代预防医学, 2007, 34(12):2239-2241. Tian M Y, Li H Y. Experimental study on the model of osteoporosis in ovariectomized rats[J].Modern Preventive Medicine,2007,34(12):2239-2241.
[12] 李旭鸿, 侯曼, 仰红慧. 骨密度的测定方法及影响因素.天津体育学院学报, 2005, 20(3):62-65. Li H X, Hou M, Yang H H. The measurement methods and influence factors of bone density. Journal of TjIPE,2005,20(3):62-65.
[13] Xiaodong L, Ominsky M S, Warmington K S, et al. Sclerostin antibody treatment increases bone formation, bone mass, and bone strength in a rat model of postmenopausal osteoporosis.Journal of Bone & Mineral Research the Official Journal of the American Society for Bone &Mineral Research, 2009, 24(4):578-588.
[14] Durlej M, Knapczyk-Stwora K, Duda M, et al. The expression of FSH receptor (FSHR) in the neonatal porcine ovary and its regulation by flutamide. Reproduction in Domestic Animals,2011, 46(3):377-384.
[15] Haberman S, Race G J. Application of immunofluorescence to study of human tumors by rabbit antibody production to nucleoprotein of human malignant tissues. Texas Medicine, 1968, 64(5):45.
[16] Heukers R, Henegouwen P M, Oliveira S. Nanobody-photosensitizer conjugates for targeted photodynamic therapy. Nanomedicine:Nanotechnology, Biology and Medicine, 2014,10(7):1441-1451.
[17] Kalu D N. The ovariectomized rat model of postmenopausal bone loss. Bone & Mineral, 1992,15(3):175-191.
[18] Liu S P, Liao E Y, Hanwen W U, et al. Comprehensive assessment of the ovariectomized rat model of postmenopausal osteoporosis. Bulletin of Hunan Medical University, 2001, 26(2):111-114.
[19] Pujol J P, Chadjichristos C, Legendre F, et al. Interleukin-1 and transforming growth factor-β1 as crucial factors in osteoarthritic cartilage metabolism. Connective Tissue Research, 2008,49(3-4):293-297. |
|
Viewed |
|
|
|
Full text
|
|
|
|
|
Abstract
|
|
|
|
|
Cited |
|
|
|
|
| |
Shared |
|
|
|
|
| |
Discussed |
|
|
|
|
